Anika Therapeutics (ANIK) Non-Current Deferred Tax Liability: 2010-2023
Historic Non-Current Deferred Tax Liability for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2023 value amounting to $2.0 million.
- Anika Therapeutics' Non-Current Deferred Tax Liability fell 71.25% to $2.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.0 million, marking a year-over-year decrease of 71.25%. This contributed to the annual value of $6.4 million for FY2022, which is 36.63% down from last year.
- Anika Therapeutics' Non-Current Deferred Tax Liability amounted to $2.0 million in Q3 2023, which was down 39.57% from $3.2 million recorded in Q2 2023.
- In the past 5 years, Anika Therapeutics' Non-Current Deferred Tax Liability ranged from a high of $16.0 million in Q1 2020 and a low of $2.0 million during Q3 2023.
- For the 3-year period, Anika Therapeutics' Non-Current Deferred Tax Liability averaged around $8.0 million, with its median value being $8.2 million (2022).
- Per our database at Business Quant, Anika Therapeutics' Non-Current Deferred Tax Liability spiked by 373.14% in 2020 and then tumbled by 71.25% in 2023.
- Over the past 5 years, Anika Therapeutics' Non-Current Deferred Tax Liability (Quarterly) stood at $4.3 million in 2019, then surged by 174.65% to $11.9 million in 2020, then fell by 14.61% to $10.2 million in 2021, then crashed by 36.63% to $6.4 million in 2022, then tumbled by 71.25% to $2.0 million in 2023.
- Its last three reported values are $2.0 million in Q3 2023, $3.2 million for Q2 2023, and $4.1 million during Q1 2023.